Background: Therapy with pergolide, an ergot-derived dopamine receptor agonist, is associated with retroperitoneal, pleural and pericardial fibrosis. The aim of this study was to investigate the relationship between the longterm use of pergolide and the prevalence of restrictive valvular heart disease. Methods: The study population consisted of 95 patients (age 61±9 years, 24% female) with Parkinson's disease (PD) treated with pergolide and 35 healthy controls matched for age and gender. All subjects underwent transthoracic echo-Doppler examination. Valve morphology was graded as normal, restrictive or degenerative. Mitral valve tenting area and tenting distance were assessed from parasternal long-axis views. Results: Average daily dose of pergolide, cumulative dose and median duration of treatment were 2.93±0.72 mg, 4543±1932 mg and 51.6±23 months, respectively. Severe valvular heart disease or pulmonary hypertension was not observed in any subject. Two PD patients (2.1%) and one control (2.9%) had moderate degenerative aortic regurgitation. Discrete fibrous thickening of the left-sided valves was noted in 16 PD patients (16.8 %) as compared to none of the controls (p<0.01). Mitral valve was affected in 10 patients and aortic valve in 6 patients. Regurgitation was not observed on any of the affected valves. Of note, in the PD patients, the mitral valve tenting area was significantly larger than in controls (1.44±0.03 cm 2 vs 1.05±0.05 cm 2 , p=0.0001).
The distribution of intensity of 2D-mode echoes within the traced area (aortic valve including aortic annulus) was displayed graphically. Obtained values of Max and Mean intensity in the 2 groups were compared using t-criteria of Student. Max is the number of data corresponding to the graduation value with the maximum number of data as a percentage of the total number of data (%). Mean is a mean value of echo intensity within the traced area. Results: Visualization of the aortic valve was performed in all cases easily. The Max value in subjects without calcification was 9.52±2.76 and in patients with aortic valve calcification -6.13±0. Aortic sclerosis (AS) is a marker of increased risk for cardiovascular events. AS incidence increases with age and in specific clinical settings, and it is thought to represent a marker of atherosclerosis. Its prevalence and determinants, however, in patients with both coronary artery disease (CAD) and peripheral artery disease (PAD) are not known. Purpose: To assess the prevalence and the determinants of AS in patients with CAD and PAD. Methods: Patients referred for echocardiography for suspected cardiac disease were prospectively enrolled in the study. Aortic sclerosis was defined by echocardiography as focal areas of increased echogenecity on aortic cusps not inducing stenosis, i.e. maximal aortic velocity < or =2.5 m/s. History of CAD, PAD, hypertension, dyslipidemia, diabetes, and smoke were assessed in each patient. 215 patients (age 69±9 years, 167 men) were divided into four age and sex matched groups: 63 had neither history of CAD nor PAD (normal), 71 had CAD, 24 had PAD, and in the remaining 57 there was history of both CAD and PAD. Results: AS was found in 66 patients; patients with AS were older than patients without (71±7 vs 64±9 years, p<0.001). AS prevalence increased significantly in patients with both CAD and PAD (Figure) . By logistic regression analysis, determinants of AS were found to be age and coexistence of CAD and PAD (p<0.001).
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